ABSTRACT
The care of small and sick neonates requires biomedical technologies, such as devices that can keep babies warm (radiant warmers and incubators), resuscitate (self-inflating bags), track growth (weighing scales), treat jaundice (phototherapy units) and provide oxygen or respiratory support (hoods, continuous positive airway pressure (CPAP) devices and ventilators). Until the 1990s, most of these products were procured through import at a high cost and with little maintenance support. Emerging demand and an informal collaboration of neonatologists, engineers and entrepreneurs has led to the production of good quality equipment of several high-volume categories at affordable cost in India. Radiant warmers, resuscitation bags, phototherapy units, weighing scales and other devices manufactured by Indian small-scale companies have enabled an expansion of neonatal care in the country, particularly in district hospitals, medical college hospitals and subdistrict facilities in the public sector as a part of the National Rural Health Mission. Indian products have acquired international quality standards and are even exported to developed nations. This paper captures this story of innovation and entrepreneurship in neonatal care.
Subject(s)
Equipment and Supplies, Hospital/statistics & numerical data , Infant Care/instrumentation , Delivery of Health Care , Equipment and Supplies, Hospital/standards , Humans , India , Infant , Infant, Newborn , Intensive Care, Neonatal/organization & administration , Neonatology/organization & administration , Outcome Assessment, Health CareABSTRACT
Huntington's disease (HD) is a progressive neurological disorder caused by a CAG/polyglutamine repeat expansion. We have previously generated the R6/2 mouse model that expresses exon 1 of the human HD gene containing CAG repeats in excess of 150. These mice develop a progressive neurological phenotype with a rapid onset and progression. We show here that it is impossible to establish fibroblast lines from these mice at 12 weeks of age, whilst this can be achieved without difficulty at 6 and 9 weeks. Cultures derived from mice at 12 weeks contained a high frequency of dysmorphic cells, including cells with an aberrant nuclear morphology and a high frequency of micronuclei and large vacuoles. All of these features were also present in a line derived from a juvenile HD patient. Fibroblast lines derived from R6/2 mice and from HD patients were found to have a high frequency of multiple centrosomes which could account for all of the observed phenotypes including a reduced mitotic index, high frequency of aneuploidy and persistence of the midbody. We were unable to detect large insoluble polyglutamine aggregates in either the mouse or human lines. We have identified a novel progressive HD pathology that occurs in cells of non-central nervous system origin. An investigation of the pathological consequences of the HD mutation in these cells will provide insight into cellular basis of the disease.
Subject(s)
Centrosome/metabolism , Fibroblasts/metabolism , Huntington Disease/genetics , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , Aneuploidy , Animals , Blotting, Western , Brain/metabolism , Cell Line , Cell Nucleus/metabolism , Cellular Senescence/genetics , Cytoplasm/metabolism , Cytoskeleton/metabolism , DNA Replication/genetics , Endocytosis , Endosomes/metabolism , Female , Fibroblasts/cytology , Humans , Huntingtin Protein , Huntington Disease/pathology , Lysosomes/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Microscopy, Fluorescence , Mitotic Index , Nerve Tissue Proteins/metabolism , Nuclear Proteins/metabolism , Trinucleotide Repeat Expansion/genetics , Trinucleotide Repeats/geneticsABSTRACT
The huntingtin interacting protein (HIP1) is enriched in membrane-containing cell fractions and has been implicated in vesicle trafficking. It is a multidomain protein containing an N-terminal ENTH domain, a central coiled-coil forming region and a C-terminal actin-binding domain. In the present study we have identified three HIP1 associated proteins, clathrin heavy chain and alpha-adaptin A and C. In vitro binding studies revealed that the central coiled-coil domain is required for the interaction of HIP1 with clathrin, whereas DPF-like motifs located upstream to this domain are important for the binding of HIP1 to the C-terminal 'appendage' domain of alpha-adaptin A and C. Expression of full length HIP1 in mammalian cells resulted in a punctate cytoplasmic immunostaining characteristic of clathrin-coated vesicles. In contrast, when a truncated HIP1 protein containing both the DPF-like motifs and the coiled-coil domain was overexpressed, large perinuclear vesicle-like structures containing HIP1, huntingtin, clathrin and endocytosed transferrin were observed, indicating that HIP1 is an endocytic protein, the structural integrity of which is crucial for maintenance of normal vesicle size in vivo.
Subject(s)
Carrier Proteins/physiology , Clathrin/chemistry , DNA-Binding Proteins , Endocytosis/physiology , Adaptor Protein Complex alpha Subunits , Animals , COS Cells , Carrier Proteins/chemistry , Carrier Proteins/metabolism , Cell Line , Clathrin/metabolism , Clathrin-Coated Vesicles/metabolism , Humans , Membrane Proteins/metabolism , Microscopy, Fluorescence , Precipitin Tests , Protein Binding , Protein Structure, Tertiary , TransferrinABSTRACT
BACKGROUND: Artesunate is a commonly used antimalarial drug derived from artemisinin. It is rapidly converted to dihydroartemisinin. Little is known on this conversion in the GI tract and blood, and how this influences absorption. In order to study the absorption phase of the kinetics of artesunate following oral administration in rats, samples were collected at baseline, and then 0.5, 2, 5, 10, 15, 30, 45, 60 and 120 minutes after a single dose of 150 mg. RESULTS: Peak concentration of parent artesunate and dihydroartemisinin was achieved within 5 and 37.5 +/- 8.7 min, respectively of start of administration through gavage. The half lives of absorption were 2.73 +/- 0.85 and 12.49 +/- 2.49 min, respectively. CONCLUSIONS: These times were considerably shorter for artesunate than those found in studies which start sampling later. The profiles of parent compound and metabolite result from a complex equation dictated by the pH-dependent rates of hydroxylation of artesunate to dihydroartemisinin, the different rates at which either compounds are absorbed, and the catalytic hydroxylation by esterases. The rate of chemical oxidation of artesunate is pH dependent; this explains its rapid conversion to dihydroartemisinin in the stomach, as compared to its greater stability in other compartments at higher pH and in plasma. We propose that variable proportions of absorption take place in the stomach, and conclude that parent artesunate reaches an early peak within minutes of dosing, and that the early dihydroartemisinin levels result primarily from the absorption of the metabolite as such.
Subject(s)
Antimalarials/pharmacokinetics , Artemisinins/pharmacokinetics , Sesquiterpenes/pharmacokinetics , Administration, Oral , Animals , Artesunate , Half-Life , Intestinal Absorption , Male , Rats , Rats, Sprague-DawleySubject(s)
Peptides/analysis , Animals , Cell Nucleus/metabolism , Huntington Disease/pathology , Immunohistochemistry/methods , Inclusion Bodies/metabolism , Macromolecular Substances , Mice , Mice, Transgenic , Microscopy, Electron/methods , Muscle, Skeletal/metabolism , Neurons/metabolism , Peptides/chemistryABSTRACT
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a CAG-polyglutamine repeat expansion. A mouse model of this disease has been generated by the introduction of exon 1 of the human HD gene carrying highly expanded CAG repeats into the mouse germ line (R6 lines). Transgenic mice develop a progressive neurological phenotype with a movement disorder and weight loss similar to that in HD. We have previously identified neuronal inclusions in the brains of these mice that have subsequently been established as the pathological hallmark of polyglutamine disease. Inclusions are present before symptoms, which in turn occur long before any selective neuronal cell death can be identified. We have extended the search for inclusions to skeletal muscle, which, like brain, contains terminally differentiated cells. We have conducted an investigation into the skeletal muscle atrophy that occurs in the R6 lines, (i) to provide possible insights into the muscle bulk loss observed in HD patients, and (ii) to conduct a parallel analysis into the consequence of inclusion formation to that being performed in brain. The identification of inclusions in skeletal muscle might be additionally useful in monitoring the ability of drugs to prevent inclusion formation in vivo.
Subject(s)
Huntington Disease/genetics , Huntington Disease/physiopathology , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , Animals , Exons , Humans , Huntingtin Protein , Mice , Mice, Transgenic , Movement Disorders/genetics , Movement Disorders/physiopathology , Peptides/genetics , Repetitive Sequences, Amino Acid , Trinucleotide RepeatsABSTRACT
Huntington's disease (HD) is one of a class of inherited progressive neurodegenerative disorders that are caused by a CAG/polyglutamine repeat expansion. We have previously generated mice that are transgenic for exon 1 of the HD gene carrying highly expanded CAG repeats which develop a progressive movement disorder and weight loss with similarities to HD. Neuronal inclusions composed of the exon 1 protein and ubiquitin are present in specific brain regions prior to onset of the phenotype, which in turn occurs long before specific neurodegeneration can be detected. In this report we have extended the search for polyglutamine inclusions to non-neuronal tissues. Outside the central nervous system (CNS), inclusions were identified in a variety of post-mitotic cells. This is consistent with a concentration-dependent nucleation and aggregation model of inclusion formation and indicates that brain-specific factors are not necessary for this process. To possibly gain insights into the wasting that is observed in the human disease, we have conducted a detailed analysis of the timing and progression of inclusion formation in skeletal muscle and an investigation into the cause of the severe muscle atrophy that occurs in the mouse model. The formation of inclusions in non-CNS tissues will be particularly useful with respect to in vivo monitoring of pharmaceutical agents selected for their ability to prevent polyglutamine aggregation in vitro, without the requirement that the agent can cross the blood-brain barrier in the first instance.
Subject(s)
Huntington Disease/genetics , Muscle, Skeletal/ultrastructure , Muscular Atrophy/genetics , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , Peptides/genetics , Animals , Cell Nucleus/genetics , Cell Nucleus/ultrastructure , Central Nervous System/pathology , Central Nervous System/physiopathology , Disease Models, Animal , Humans , Huntingtin Protein , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Skeletal/pathology , Muscle, Skeletal/pathology , Muscular Atrophy/physiopathology , Neurons/pathologyABSTRACT
The puffer fish ( Fugu rubripes ) has a compact genome of 400 Mbp which is approximately 7.5-fold smaller than the human genome. It contains a similar number of genes but is deficient in intergenic, intronic and dispersed repetitive sequences. Fugu is becoming established as the model vertebrate genome for the identification and characterisation of novel human genes and conserved regulatory sequences. It has also been proposed that Fugu genes may provide natural mini-genes for the production of transgenic mice. We have used the Fugu homologue of the Huntington's disease (HD) gene to test this possibility. The human and Fugu HD genes cover 170 kb and 23 kb respectively and have previously been sequenced in their entirety. In Fugu tissue, the Fugu HD gene was found to be expressed as predicted from the gene sequence but three differentially spliced forms were also detected. Despite the absence of conserved promoter sequences, the Fugu promoter was found to be functional in mouse cells. We have generated mice transgenic for the Fugu HD gene and conducted a detailed expression analysis across the entire 10 kb transcript. This revealed the presence of many aberrant splice forms which would be incompatible with the production of the Fugu huntingtin protein. The Fugu HD gene is incorrectly processed in mouse cells both in vitro and in vivo which sheds doubt on the usefulness of Fugu genes for transgenesis.
Subject(s)
Fishes, Poisonous/genetics , Huntington Disease/genetics , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , RNA Processing, Post-Transcriptional , RNA, Messenger/genetics , RNA, Messenger/metabolism , Animals , Cell Line , Huntingtin Protein , Mice , Mice, Transgenic , Promoter Regions, GeneticABSTRACT
The derivation of murine, embryonic stem cells, and their use in the generation of transgenic mice, are well-established procedures. Application of these methodologies to non-murine species, however, remains to be fully realized. Non-murine embryonic stem cells would be of considerable value to studies in comparative development, and would raise important implications for agriculture and biotechnology. Here we report the achievement of chimerism and transgenesis in the domestic pig (Sus scrofa) at a fetal stage by the embryonic stem-cell methodology, using an embryonic cell line which previously we described as having the capacity to differentiate in vitro. This entailed: transformation, by electroporation, of a cell line, PE1, with the bacterial gene for neomycin-resistance; re-introduction of a polyclonal population of neo-PE1 cells into host blastocysts, followed by transfer of reconstructed embryos into a pseudopregnant recipient; and subsequent derivation of transgenic and chimeric porcine fetuses, as determined by two independent molecular assays of fetal genomic DNA. In the first instance, chimerism was revealed in one fetus by the presence of the transgene, as detected by Southern blotting; and in the second instance, in that and another fetus by the presence of supernumerary alleles for the class II major histocompatibility locus, SLA-DQB*C, by single-strand conformation polymorphic analysis. The contribution of neo-PE1 cells to the first chimeric and transgenic fetus was approximately 25%, and to the second chimeric fetus, below the level of detection by Southern blotting (i.e. less than 10%). The results indicate that, at the time of embryo reconstitution, a proportion of neo-PE1 cells were pluripotent and of the primary ectodermal lineage.
Subject(s)
Animals, Genetically Modified/physiology , Chimera/physiology , Fetus/physiology , Stem Cells/physiology , Swine/embryology , Animals , Blotting, Southern , Cells, Cultured , Electroporation/methods , Stem Cells/cytology , Transformation, GeneticABSTRACT
The Huntington's disease mutation has been identified as a CAG/polyglutamine repeat expansion in a large gene of unknown function. In order to develop the transgenic systems necessary to uncover the molecular pathology of this disorder, it is necessary to be able to manipulate highly expanded CAG repeats in a cloned form. We have identified a patient with an expanded allele of greater than 170 repeat units and have cloned the mutant allele in the lambda zap vector. The recovery of highly expanded repeats after clone propagation was more efficient when repeats were maintained as lambda phage clones rather than as the plasmid counterparts. Manipulation of the repeats as phage clones has enabled us to generate Huntington's disease transgenic mice that contain highly expanded (CAG)115-(CAG)150 repeats and that develop a progressive neurological phenotype.
Subject(s)
Huntington Disease/genetics , Trinucleotide Repeats , Animals , Bacteriophage lambda , Base Sequence , Cloning, Molecular , DNA Primers , Escherichia coli , Genetic Vectors , Genomic Library , Glutamine , Humans , Mice , Mice, Transgenic , Polymerase Chain ReactionABSTRACT
Six inherited neurodegenerative diseases are caused by a CAG/polyglutamine expansion, including spinal and bulbar muscular atrophy (SBMA), Huntington's disease (HD), spinocerebellar ataxia type 1 (SCA1), dentatorubral pallidoluysian atrophy (DRPLA) Machado-Joseph disease (MJD or SCA3) and SCA2. Normal and expanded HD allele sizes of 6-39 and 35-121 repeats have been reported, and the allele distributions for the other diseases are comparable. Intergenerational instability has been described in all cases, and repeats tend to be more unstable on paternal transmission. This may present as larger increases on paternal inheritance as in HD, or as a tendency to increase on male and decrease on female transmission as in SCA1 (ref. 15). Somatic repeat instability is also apparent and appears most pronounced in the CNS. The major exception is the cerebellum, which in HD, DRPLA, SCA1 and MJD has a smaller repeat relative to the other brain regions tested. Of non-CNS tissues, instability was observed in blood, liver, kidney and colon. A mouse model of CAG repeat instability would be helpful in unravelling its molecular basis although an absence of CAG repeat instability in transgenic mice has so far been reported. These studies include (CAG) in the androgen receptor cDNA, (CAG) in the HD cDNA, (CAG) in the SCA1 cDNA, (CAG) in the SCA3 cDNA and as an isolated (CAG) tract.
Subject(s)
Huntington Disease/genetics , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , Transgenes/genetics , Trinucleotide Repeats , Animals , Female , Humans , Huntingtin Protein , Male , Mice , Mice, Transgenic , Mosaicism , Mutation , Organ Specificity , Polymerase Chain Reaction , Reproducibility of ResultsABSTRACT
Huntington's disease (HD) is one of an increasing number of neurodegenerative disorders caused by a CAG/polyglutamine repeat expansion. Mice have been generated that are transgenic for the 5' end of the human HD gene carrying (CAG)115-(CAG)150 repeat expansions. In three lines, the transgene is ubiquitously expressed at both mRNA and protein level. Transgenic mice exhibit a progressive neurological phenotype that exhibits many of the features of HD, including choreiform-like movements, involuntary stereotypic movements, tremor, and epileptic seizures, as well as nonmovement disorder components. This transgenic model will greatly assist in an eventual understanding of the molecular pathology of HD and may open the way to the testing of intervention strategies.